Moxifloxacin causes rapid improvement in exacerbations of chronic bronchitis
Chronic bronchitis, defined as a disease of the lower respiratory tract, accompanied by coughing and elimination of sputum, is a common disease that causes the patient to become incapacitated over time.
Chronic bronchitis, defined as a disease of the lower respiratory tract accompanied by coughing and elimination of sputum for at least 3 months of the year for 2 consecutive years, is a common disease (fifth in the list of the most common in the world), leading over time to patient incapacity. The main factors in the pathogenesis of chronic bronchitis are the long-term effects of pollutants and smoking. Exacerbations of chronic bronchitis (ACB) are understood to be recurrent episodes of deterioration in patients with chronic bronchitis, characterized by increased cough, onset or intensification of shortness of breath, and increased number and / or a change in the quality of sputum that becomes purulent. There are various reasons for the development of BCS, but it is believed that bacterial infection plays a role in about half of the cases of exacerbations.
The need to use antibiotics in all cases of exacerbations of chronic bronchitis remains controversial, but it has been proven that in most patients, especially in severe exacerbations, antibiotic therapy leads to marked clinical improvement , improves quality of life, inhibits disease progression, prevents the development of complications and reduces the risk of death. results in the later stages of the disease.
In a post-marketing epidemiological study in Germany, the efficacy and tolerability of 400 mg moxifloxacin once daily was studied orally for the treatment of exacerbations of chronic bronchitis on an outpatient basis. In addition, the timing of the onset of clinical effect was examined, as well as the assessment by physicians and patients of the treatment of OXB with moxifloxacin compared to treatment with macrolide antibiotics.
An open, non-comparable, multicentre, open observational study included 7,223 OCD patients (52.9% males, 47.1% females) who received treatment for this exacerbation with moxifloxacin and had a history of treatment for the previous exacerbation with macrolide antibiotics. Most patients (67.0%) received moxifloxacin for BCS for 5 days, 20.7% for 6-7 days.
According to estimates by the treating physicians, 75.9% (n = 5482) of the patients had clinical recovery and 22.3% (n = 1610) of the patients had clinical improvement at the end of the observation period. Improvement was noted on the 3rd day of treatment in 75% of patients, and on the 5th day of treatment - in 99.9% of patients, recovery occurred on average after 6.2 days of treatment.
Over 70% of treating physicians noted that the clinical effect in the treatment of exacerbations of chronic bronchitis with moxifloxacin occurs faster than with macrolide antibiotics. In addition, treatment with moxifloxacin was well tolerated - 97.8% of patients rated the medication as "very good" and "good". The most common side effects (NLR) of moxifloxacin were dizziness and abdominal pain, while the overall incidence of marked NLR was 0.7%.
Thus, a short therapy with moxifloxacin, administered orally once a day, is very effective and well tolerated, causing rapid improvement in patients with exacerbations of chronic bronchitis.